- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05862688
A Cohort Study on Anti-microbial Stewardship in PICU
February 6, 2024 updated by: Children's Hospital of Fudan University
Appropriate antimicrobial therapy is essential to ensuring positive patient outcomes.
Inappropriate or suboptimal utilization of antibiotics can lead to increased length of stay, multidrug-resistant infections, and mortality.
Critically ill intensive care patients are at risk of antibiotic failure and secondary infections associated with incorrect antibiotic use.
Initiating effective therapy for infections based upon patients' risk factors, collection of appropriate cultures, daily evaluation of clinical status, and laboratory data, including antibiotic time outs, and shortened duration of therapy are ways to improve patients outcomes.
Antimicrobial stewardship teams can assist ICU providers in managing and implementing these tactics.
ICUs would benefit from employing empiric guidelines for antibiotic use, collecting appropriate specimens and implementing molecular diagnostics, optimizing the dosing of antibiotics, and reducing the duration of total therapy.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
Appropriate antimicrobial therapy is essential to ensuring positive patient outcomes.
Inappropriate or suboptimal utilization of antibiotics can lead to increased length of stay, multidrug-resistant infections, and mortality.
Critically ill intensive care patients are at risk of antibiotic failure and secondary infections associated with incorrect antibiotic use.
Initiating effective therapy for infections based upon patients' risk factors, collection of appropriate cultures, daily evaluation of clinical status, and laboratory data, including antibiotic time outs, and shortened duration of therapy are ways to improve patients outcomes.
Antimicrobial stewardship teams can assist ICU providers in managing and implementing these tactics.
ICUs would benefit from employing empiric guidelines for antibiotic use, collecting appropriate specimens and implementing molecular diagnostics, optimizing the dosing of antibiotics, and reducing the duration of total therapy.
This study conducted an antibiotic management cohort study in PICUs to discover the distribution of nosocomial infections in PICUs and to find controllable factors for the occurrence of nosocomial infections.
Study Type
Observational
Enrollment (Estimated)
1000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jing Liu, Doctor
- Phone Number: 15800523953
- Email: liujinggg@126.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
ICU patient
Description
Inclusion Criteria:
- Patients admitted to the ICU for more than 48 hour
Exclusion Criteria:
- Patients admitted to ICU less than 48 hours
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Infection
patients with infection
|
antimicrobial therapy
|
non-infection
patients without infection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
survival rate
Time Frame: 21 days after ICU admission
|
the survival rate of children in 21 days after ICU admission
|
21 days after ICU admission
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the length of ICU stay time
Time Frame: 21 days after ICU admission
|
the length of ICU stay time
|
21 days after ICU admission
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 1, 2024
Primary Completion (Estimated)
June 1, 2025
Study Completion (Estimated)
June 1, 2025
Study Registration Dates
First Submitted
February 26, 2023
First Submitted That Met QC Criteria
May 8, 2023
First Posted (Actual)
May 17, 2023
Study Record Updates
Last Update Posted (Actual)
February 7, 2024
Last Update Submitted That Met QC Criteria
February 6, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- fdpicu-29
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infections
-
International Centre for Diarrhoeal Disease Research...Centers for Disease Control and PreventionNot yet recruitingMeasles | Rubella | Cholera | Typhoid
-
MJM BontenJanssen Research & Development, LLC; Innovative Medicines InitiativeCompletedE.Coli InfectionsUnited States, United Kingdom, Canada, France, Germany, Italy, Japan, Spain
-
PfizerCompletedGroup B Streptococcus InfectionsUnited States, South Africa, United Kingdom
-
GlaxoSmithKlineActive, not recruitingInfections, MeningococcalFinland, Poland, Spain, United Kingdom, Germany, South Africa, Dominican Republic, Israel, Honduras
-
PfizerCompletedInfections, MeningococcalAustralia, Canada, Czechia, Panama, South Africa, Turkey
-
GlaxoSmithKlineCompletedInfections, MeningococcalFinland
-
PfizerCompletedInfections, MeningococcalPhilippines
-
GlaxoSmithKlineCompletedInfections, MeningococcalUnited States, Finland, Poland
-
GlaxoSmithKlineCompleted
Clinical Trials on antimicrobial therapy
-
Fundación Pública Andaluza para la gestión de la...Completed
-
Hamad Medical CorporationCompletedEscherichia Coli Bacteremia | Klebsiella Bacteraemia | Enterobacter Bacteraemia | Serratia Bacteraemia | Citrobacter Bacteraemia | Proteus BacteraemiaQatar, Turkey, Bahrain, Kuwait
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Universidade Federal FluminenseCompleted
-
Kafrelsheikh UniversityRecruitingAggressive Periodontitis | Photodynamic Therapy | L-PRFEgypt
-
Oslo University HospitalRecruitingInfectious Disease | Bacterial Overgrowth | Pigment DepositionNorway
-
French Society for Intensive CareRecruitingVentilator Associated PneumoniaFrance
-
Lawson Health Research InstituteRecruitingInfective EndocarditisCanada
-
University of Lausanne HospitalsRecruiting
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompleted